Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Patient screening and enrollment are active, with the aim of enrolling 80 patients internationally in the overall Phase I/II trial.
- Patient screening and enrollment are active, with the aim of enrolling 80 patients internationally in the overall Phase I/II trial.
- The therapeutic vaccine, TG4050, is being jointly developed by Transgene and NEC in head and neck cancer.
- TG4050 advancing to Phase II part based on Phase I data showing immunogenicity and first signs of clinical benefit.
- TG4050 is the only individualized neoantigen cancer vaccine currently being developed in a randomized trial in the adjuvant treatment of head and neck cancer.